Favipiravir
-
{
- All
- News
- Videos
-
EU Secures Emergency Deliveries Of Potential Treatment Against Hantavirus
The European Union is launching emergency procurement procedures to secure additional doses in case further hantavirus cases are confirmed in the coming weeks.
-
Baby's Dark-Brown Eyes Turn Blue After Covid-19 Treatment In Thailand: Report
The dark brown eyes of a 6-month-old infant in Thailand temporarily turned indigo blue after receiving a common COVID-19 treatment.
-
19 States Mapped With Remdesivir Manufacturers For Faster Supply
The centre has mapped manufacturers of the anti-viral drug remdesivir with 19 states that have high Covid case burden. This will ensure smooth and fast delivery of the medicine, the centre said in a statement.
-
COVID-19: Supreme Court Seeks Centre's Reply On Plea Claiming No Approval For Remdesivir
The Supreme Court today sought the Centre's reply on a plea alleging that two medicines Remdesivir and Favipiravir, are being used for treatment of COVID-19 without approval.
-
Lupin Launches COVID-19 Drug Favipiravir In India At Rs 49 Per Tablet
Drug major Lupin on Wednesday announced the launch of its Favipiravir drug under the brand name "Covihalt" for the treatment patients with mild to moderate COVID-19 symptoms at Rs 49 per tablet in India.
-
Sun Pharma Company Launches COVID-19 Drug Favipiravir In India
Sun Pharmaceutical Industries has said it has launched Favipiravir (200 mg) in India under the brand FluGuard at an economical price of Rs 35 per tablet for the treatment of mild to moderate cases of COVID-19.
-
Cipla Set To Launch Favipiravir Drug For Treatment Of COVID Patients
Pharmaceutical firm Cipla is all set to launch Favipiravir, developed by the Council of Scientific and Industrial Research (CSIR) in a cost-effective process, for the treatment of COVID-19 patients, according to an official statement on Thursday.
-
Glenmark Launches COVID-19 Drug Favipiravir At Rs 103 Per Tablet
As Glenmark Pharmaceuticals launched antiviral drug Favipiravir for the treatment of mild to moderate COVID-19 cases, medical experts on Saturday cautioned against seeing it as a "magic bullet" to treat the deadly virus but said it will be helpful as it can be orally administered and reduce viral load.
-
Research Body CSIR To Begin Two Drug Trials For COVID-19
The Council for Scientific and Industrial Research (CSIR) has received approval from Drug Controller General of India (DGCI) for its two clinical trial drugs - ''favipiravir'' and ''phytopharmaceutical'' - to combat coronavirus.
-
EU Secures Emergency Deliveries Of Potential Treatment Against Hantavirus
The European Union is launching emergency procurement procedures to secure additional doses in case further hantavirus cases are confirmed in the coming weeks.
-
Baby's Dark-Brown Eyes Turn Blue After Covid-19 Treatment In Thailand: Report
The dark brown eyes of a 6-month-old infant in Thailand temporarily turned indigo blue after receiving a common COVID-19 treatment.
-
19 States Mapped With Remdesivir Manufacturers For Faster Supply
The centre has mapped manufacturers of the anti-viral drug remdesivir with 19 states that have high Covid case burden. This will ensure smooth and fast delivery of the medicine, the centre said in a statement.
-
COVID-19: Supreme Court Seeks Centre's Reply On Plea Claiming No Approval For Remdesivir
The Supreme Court today sought the Centre's reply on a plea alleging that two medicines Remdesivir and Favipiravir, are being used for treatment of COVID-19 without approval.
-
Lupin Launches COVID-19 Drug Favipiravir In India At Rs 49 Per Tablet
Drug major Lupin on Wednesday announced the launch of its Favipiravir drug under the brand name "Covihalt" for the treatment patients with mild to moderate COVID-19 symptoms at Rs 49 per tablet in India.
-
Sun Pharma Company Launches COVID-19 Drug Favipiravir In India
Sun Pharmaceutical Industries has said it has launched Favipiravir (200 mg) in India under the brand FluGuard at an economical price of Rs 35 per tablet for the treatment of mild to moderate cases of COVID-19.
-
Cipla Set To Launch Favipiravir Drug For Treatment Of COVID Patients
Pharmaceutical firm Cipla is all set to launch Favipiravir, developed by the Council of Scientific and Industrial Research (CSIR) in a cost-effective process, for the treatment of COVID-19 patients, according to an official statement on Thursday.
-
Glenmark Launches COVID-19 Drug Favipiravir At Rs 103 Per Tablet
As Glenmark Pharmaceuticals launched antiviral drug Favipiravir for the treatment of mild to moderate COVID-19 cases, medical experts on Saturday cautioned against seeing it as a "magic bullet" to treat the deadly virus but said it will be helpful as it can be orally administered and reduce viral load.
-
Research Body CSIR To Begin Two Drug Trials For COVID-19
The Council for Scientific and Industrial Research (CSIR) has received approval from Drug Controller General of India (DGCI) for its two clinical trial drugs - ''favipiravir'' and ''phytopharmaceutical'' - to combat coronavirus.
